- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03905837
Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery
Impact of the Administration of Intravenous or Paravertebral Lidocaine in Continuous Perfusion During the Intraoperative Period of Lung Resection Surgery on the Appearance of Postoperative Complications
Study Overview
Status
Intervention / Treatment
Detailed Description
Postoperative pulmonary complications continue to be one of the main causes of morbidity, mortality and increase in hospital stay in patients undergoing surgical procedures requiring anesthesia. Its incidence in lung resection surgery is greater than in other non-cardiac major surgeries due to damage of structures related to respiratory function.
Furthermore, during lung resection surgery there is an exaggerated pulmonary inflammatory response related to the use of one-lung ventilation and / or the lung damage produced by the collapse of the operated lung as well as the surgical manipulation itself.
Recently, in a clinical trial on 180 patients (NCT 02168751), our researcher group observed that the attenuation of the pulmonary inflammatory response through the use of halogenated anesthetic agents, was related to a decrease in the appearance of postoperative pulmonary complications after lung resection surgery. In addition, the presence, in bronchoalveolar lavages, of elevated levels of tumor necrosis factor-alpha, interleukine(IL)-6 and the IL-6 / IL10 ratio were independent predictors of the risk of developing postoperative pulmonary complications.
Lidocaine is a local anesthetic that blocks nerve conduction by blocking sodium channels. In addition it has been known for experimental and clinical studies of its immunomodulatory properties.
Clinical studies performed in different surgeries show that a continuous intravenous infusion of lidocaine during surgery is associated with a lower inflammatory response assessed by monitoring plasma cytokines, as well as less postoperative pain, a shorter duration of postoperative paralytic ileus and a early hospital discharge.
Currently, there is no clinical study that has evaluated the role of intravenous lidocaine on the pulmonary inflammatory response and the subsequent lung damage that inevitably occurs during lung resection surgery with periods of one lung ventilation.
Currently, some experts are proposing the replacement of thoracic epidural and paravertebral analgesia by the intravenous infusion of lidocaine and minor analgesics, for fast-track programs, based on their analgesic and anti-inflammatory capacity and on avoiding the risks inherent in the insertion of an epidural or paravertebral catheter.
Hypothesis: The administration of intravenous or paravertebral lidocaine during lung resection surgery attenuates the exaggerated inflammatory response that inevitably occurs in this surgical intervention. The lower expression of pro-inflammatory mediators will be associated with a lower rate of postoperative complications that are related to the perioperative inflammatory process.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28007
- Hospital Gregorio Marañón
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients of both sexes undergoing lung resection surgery at the Thoracic Surgery Service at the Gregorio Maranón hospital.
- Patients who voluntarily accept to participate in the study and sign the informed consent
- Age> 18 years and legally capable
- Scheduled surgery.
- Functional respiratory tests with forced expiratory volume at one second > 50% or forced vital capacity > 50% preoperatively performed on these patients routinely.
- Not having been on chronic treatment with oral corticosteroids or immunosuppressants three months before surgery.
- Patients without previous history of liver disease.
Exclusion Criteria:
- Pregnancy and lactation
- Known hypersensitivity to amide-type local anesthetics.
- Transfusion of blood products in the previous 10 days.
- Impossibility of performing mechanical ventilation for pulmonary protection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lidocaine IV
Group 1: intravenous lidocaine and paravertebral saline (SF).
In this group during intraoperative anesthetic maintenance, a continuous intravenous infusion of lidocaine at 1.5mg/kg/h until the end of surgery and perfusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1ml/kg/h will be administered.
|
Intravenous or paravertebral lidocaine
Other Names:
|
EXPERIMENTAL: Lidocaine PV
Group 2: intravenous SF and paravertebral lidocaine.
During anesthesia maintenance, a continuous intravenous infusion of 0.9% SF and an infusion of 2% lidocaine will be administered through the intraoperative paravertebral catheter at a rate of 0.1 ml/kg/h.
|
Intravenous or paravertebral lidocaine
Other Names:
|
ACTIVE_COMPARATOR: no lidocaine
Group 3: intravenous remifentanil and paravertebral SF.
During the maintenance of anesthesia, a continuous intravenous infusion of remifentanil at a rate of 0.1 mg/kg/min until the end of surgery and an infusion of 0.9% SF through the intraoperative paravertebral catheter at a rate of 0.1 ml / kg / h.
|
intravenous remifentanil
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative complications
Time Frame: up to 30 days after intervention
|
to compare the proportion of patients included in the different scales of the Clavien-Dindo classification of postoperative complications reviewed for thoracic surgery in the three groups of patients.
Patients will be followed from the day of hospital admission until hospital discharge and up to 30 days after the surgery
|
up to 30 days after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
gas exchange
Time Frame: 24 hours
|
Compare the gas exchange (PaO2 / FiO2) at 24 hours after the intervention between the three groups of the study.
|
24 hours
|
Differences between three groups in Inflammatory biomarkers (IL 1, IL 2, IL 6, IL 8, IL 10, TNF alpha, MCP-1) measure in serum and bronchoalveolar lavage during 24 hours after the surgery.
Time Frame: up to 24 hours of intervention
|
To evaluate the effect of intravenous lidocaine on the inflammatory response in lung resection surgery by measuring the inflammatory biomarkers (Interleukin(IL) 1, IL 2, IL 6, IL8, IL 10, tumor necrosis factor alfa and monocyte chemoattractant protein) in serum and in bronchoalveolar lavage, compared to the other two groups of patients.
Blood samples are taken at the beginning of the surgery, at the end of the one lung ventilation, and at 24 hours postoperatively.
Bronchoalveolar lavage is done just before the beginning of one lung ventilation and at the end of one lung ventilation
|
up to 24 hours of intervention
|
Analgesic requirements of opioids in the first 24 hours after the surgery
Time Frame: 24 hours
|
To compare the analgesic requirements of opioids in the immediate postoperative period (first 24 hours after the surgery) between the three groups of the study.
When patients will be admitted in the postoperative care Unit a patient controlled analgesia pump of intravenous morphine 0,1% (bolus of 1mg) will be connected.
The total dose of morphine self-administered by the patient in the first 24 hours after surgery will be recorded.
|
24 hours
|
Special Care Units stay
Time Frame: up to 30 days after intervention
|
To compare the average stay (measure in hours) in Special Care Units among the three groups of the study
|
up to 30 days after intervention
|
Hospital stay
Time Frame: up to 30 days after intervention
|
To compare the average hospital stay (measure in days) among the three groups of the study
|
up to 30 days after intervention
|
Re-admissions in Special Care Units
Time Frame: up to 30 days after intervention
|
To compare the number of re-admissions in Special Care Units among the three groups of the study in the 30 days after the intervention.
|
up to 30 days after intervention
|
Postoperative cognitive dysfunction measure by mini mental state examination
Time Frame: up to 3 days after intervention
|
To analyze the incidence of postoperative cognitive dysfunction (POCD) in the three groups by comparing the mini mental state examination performed at admission and 3 days after the intervention.
|
up to 3 days after intervention
|
Neuro-inflammatory response measure by the synthesis of protein S-100 beta in serum
Time Frame: up to 24 hours after intervention
|
To evaluated the neuro-inflammatory response by the synthesis of protein S-100 beta measured in serum in the first 24 hours postoperatively in the three groups of patients.
Blood samples are taken at the beginning of the surgery, at the end of the one lung ventilation, and at 24 hours postoperatively
|
up to 24 hours after intervention
|
Neuro-inflammatory response measure by the synthesis of neuronal specific enolase in serum
Time Frame: up to 24 hours after intervention
|
To evaluated the neuro-inflammatory response by the synthesis of neuronal specific enolase measured in serum in the first 24 hours postoperatively in the three groups of patients.
Blood samples are taken at the beginning of the surgery, at the end of the one lung ventilation, and at 24 hours postoperatively
|
up to 24 hours after intervention
|
Neuro-inflammatory response measure by the synthesis of glial fibrillary acidic protein
Time Frame: up to 24 hours after intervention
|
To evaluated the neuro-inflammatory response by the synthesis of glial fibrillary acidic protein measured in serum in the first 24 hours postoperatively in the three groups of patients.
Blood samples are taken at the beginning of the surgery, at the end of the one lung ventilation, and at 24 hours postoperatively
|
up to 24 hours after intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Francisco de la Gala, MD PhD, Hospital Gregorio Marañón
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Wounds and Injuries
- Thoracic Injuries
- Lung Diseases
- Inflammation
- Pneumonia
- Postoperative Complications
- Acute Lung Injury
- Lung Injury
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Remifentanil
- Lidocaine
- Piperidine
Other Study ID Numbers
- IGMFGG-2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Diseases
-
Aveiro UniversityFundação para a Ciência e a TecnologiaNot yet recruitingInterstitial Lung DiseasesPortugal
-
RWTH Aachen UniversityCompletedObstructive Lung DiseasesGermany
-
Guangzhou Institute of Respiratory DiseaseUnknownInterstitial Lung Disease | Transbronchial Lung Cryobiopsy | Surgical Lung Biopsy
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
Shanghai East HospitalRegend TherapeuticsCompletedInterstitial Lung DiseasesChina
-
China-Japan Friendship HospitalXiangya Hospital of Central South University; Peking Union Medical College... and other collaboratorsUnknown
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedInterstitial Lung DiseasesNetherlands
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaRecruitingInterstitial Lung Diseases (ILD)Portugal
-
China-Japan Friendship HospitalNot yet recruitingTransbronchial Lung Cryobiopsy
Clinical Trials on Lidocaine
-
Ohio State UniversityCompleted
-
Khon Kaen UniversityNot yet recruitingIntubation | Hemodynamics | Laryngoscopy | Neurosurgery | LidocaineThailand
-
Aswan University HospitalUnknown
-
Benha UniversityCompletedPostcesarean Pain Relief
-
McMaster UniversitySt. Joseph's Healthcare HamiltonWithdrawnIntravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel SurgeryBariatric Surgery Candidate
-
Scilex Pharmaceuticals, Inc.Completed
-
Scilex Pharmaceuticals, Inc.Completed
-
Oregon Health and Science UniversityCompleted
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownPostoperative PainKorea, Republic of
-
Hopital FochCompleted